https://scholars.lib.ntu.edu.tw/handle/123456789/582127
Title: | Prevention of hepatocellular carcinoma in hepatitis B virus infection | Authors: | Lim S.G. Mohammed R. Yuen M.-F. JIA-HORNG KAO |
Keywords: | Cirrhosis; HBV DNA; HBV vaccine; Interferon; Lamivudine; Nucleoside analogues | Issue Date: | 2009 | Publisher: | Blackwell Publishing | Journal Volume: | 24 | Journal Issue: | 8 | Start page/Pages: | 1352-1357 | Source: | Journal of Gastroenterology and Hepatology (Australia) | Abstract: | Chronic hepatitis B is the main risk factor for hepatocellular carcinoma (HCC) in Asia. The most important preventive strategy's adoption of the universal hepatitis B vaccination program is now in its third decade. There is a clear reduction in both chronic hepatitis B virus (HBV) infection (hepatitis B surface antigen "carriage") but also in childhood HCC in Taiwan. An outstanding concern is variability in vaccine coverage between countries. For patients with chronic hepatitis B, serum HBV DNA levels have emerged as the key risk factor for development of HCC. The initial treatment for chronic hepatitis B was interferon. One randomized control trial, and several case-control or cohort studies have shown benefits for preventing HCC, particularly in cirrhotic patients who responded to therapy. With nucleos(t)ide analogs, the most important study has been the Asian Cirrhosis Lamivudine multicenter randomized controlled trial. This showed that lamivudine can reduce disease progression in HBV-related cirrhosis, including an approximately 50% decrease in HCC incidence. Such efficacy was achieved despite emergence of drug resistance in approximately 50% of cases. Case-control studies have suggested that hepatitis B cases without cirrhosis may also benefit. In conclusion, it is now possible to prevent HBV-related HCC. The most effective method is hepatitis B vaccination, which prevents chronic HBV infection and chronic liver disease resulting therefrom. Interferon therapy appears to confer benefit but the evidence is weaker. First-generation oral antiviral (lamivudine) reduces HCC risk, particularly in cirrhotics. Long-term outcome data with newer, more potent HBV antivirals that have a higher genetic barrier to drug resistance are eagerly awaited. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-69049092778&doi=10.1111%2fj.1440-1746.2009.05985.x&partnerID=40&md5=ef265125acdc8c07064ddd56daa985c0 https://scholars.lib.ntu.edu.tw/handle/123456789/582127 |
ISSN: | 0815-9319 | DOI: | 10.1111/j.1440-1746.2009.05985.x | SDG/Keyword: | alpha interferon; alpha2a interferon; hepatitis B vaccine; interferon; lamivudine; lymphoblast interferon; nucleotide derivative; prednisolone; cancer incidence; case control study; chronic liver disease; clinical trial; disease course; drug efficacy; hepatitis B; Hepatitis B virus; human; liver cell carcinoma; liver cirrhosis; priority journal; review; risk reduction; treatment outcome; treatment response; vaccination |
Appears in Collections: | 臨床醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.